Fresenius Medical Care AG

NYSE:FMS Stock Report

Market Cap: US$13.8b

Fresenius Medical Care Future Growth

Future criteria checks 2/6

Fresenius Medical Care is forecast to grow earnings and revenue by 19.3% and 3.9% per annum respectively. EPS is expected to grow by 18% per annum. Return on equity is forecast to be 7.7% in 3 years.

Key information

19.3%

Earnings growth rate

18.0%

EPS growth rate

Healthcare earnings growth20.8%
Revenue growth rate3.9%
Future return on equity7.7%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Fresenius Medical Care: Let's Look At The Upside

Oct 04

Fresenius Medical Care: Significant Upside Remains

Jun 25

Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns

Feb 23

Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off

Oct 12

Fresenius Medical Care: Other Stocks Still Better, But Upside Exists

Jun 01

Fresenius Medical Care Q4 2022 Earnings Preview

Feb 21

Fresenius: The Company Is Climbing, And I'm At 'Buy'

Jan 06

Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)

Oct 27

Fresenius Medical gains after report of activist Elliott stake in Fresenius SE

Oct 19

Fresenius cut to Hold at Jefferies citing staffing issues and inflation

Oct 10

Fresenius gets award to provide dialysis services to U.S. military veterans

Aug 30

Fresenius appoints head of pharma unit as new CEO

Aug 19

Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat

Jul 30

Fresenius Medical Care accused of Medicare fraud in dialysis

Jul 13

Fresenius: The Upside Is Getting Bigger

May 02

You Really Want To Know About Fresenius Medical Care

Aug 28

Fresenius Medical drops 12% on disappointing 2021 outlook

Feb 02

Fresenius Medical Care EPS beats by €0.06, misses on revenue

Oct 29

Earnings and Revenue Growth Forecasts

NYSE:FMS - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202620,6801,1051,8822,72016
12/31/202519,9099381,9502,55718
12/31/202419,2546811,8002,58118
9/30/202419,2396591,5382,274N/A
6/30/202419,4155301,3422,049N/A
3/31/202419,4744841,9112,613N/A
12/31/202319,4544991,9182,629N/A
9/30/202319,4634501,7992,509N/A
6/30/202319,6225961,6742,407N/A
3/31/202319,5546021,4012,152N/A
12/31/202219,3986731,3972,167N/A
9/30/202219,0487631,4442,237N/A
6/30/202218,3938061,4442,271N/A
3/31/202217,9578781,5762,441N/A
12/31/202117,6199691,6032,489N/A
9/30/202117,3729181,4772,405N/A
6/30/202117,3449981,4802,459N/A
3/31/202117,5811,1312,8693,857N/A
12/31/202017,8591,1643,1484,233N/A
9/30/202018,0391,3303,2994,420N/A
6/30/202018,0441,3093,3774,542N/A
3/31/202017,8321,2121,8323,075N/A
12/31/201917,4771,2001,4042,567N/A
9/30/201917,1961,2821,3672,494N/A
6/30/201916,8351,2341,2462,379N/A
3/31/201916,7041,9741,0652,182N/A
12/31/201816,5471,9829202,062N/A
9/30/201816,6761,9517661,892N/A
6/30/201816,9541,975N/A1,750N/A
3/31/201817,2111,250N/A1,977N/A
12/31/201717,7841,280N/A2,192N/A
9/30/201717,7711,249N/A2,436N/A
6/30/201717,6471,244N/A2,217N/A
3/31/201717,2011,239N/A1,938N/A
12/31/201616,5701,144N/A1,932N/A
9/30/201616,1011,063N/A1,648N/A
6/30/201615,841998N/A1,782N/A
3/31/201615,402933N/A1,491N/A
12/31/201515,455955N/A1,767N/A
9/30/201515,345939N/A1,791N/A
6/30/201515,246948N/A1,914N/A
3/31/201515,428977N/A2,044N/A
12/31/201413,329864N/A1,538N/A
9/30/201412,413839N/A1,476N/A
6/30/201411,112775N/A1,283N/A
3/31/201410,882791N/A1,329N/A
12/31/201310,816806N/A1,478N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FMS's forecast earnings growth (19.3% per year) is above the savings rate (2.6%).

Earnings vs Market: FMS's earnings (19.3% per year) are forecast to grow faster than the US market (15.3% per year).

High Growth Earnings: FMS's earnings are forecast to grow, but not significantly.

Revenue vs Market: FMS's revenue (3.9% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: FMS's revenue (3.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: FMS's Return on Equity is forecast to be low in 3 years time (7.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 22:44
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresenius Medical Care AG is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Brian WilliamsAvondale Partners
Olav ZilianBaader Helvea Equity Research